Stocks · News reference

Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial

Aug 13, 2026, 6:05 PMVandana Singh

Clearmind Medicine advances the CMND-100 clinical trial for alcohol use disorder to Parts B and C following positive Phase A safety data.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 13, 2026, 6:05 PM
Checked: Aug 13, 2026, 6:05 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 24, 2026, 12:07 PMBenzinga Newsdesk
Clearmind Medicine Advances Its IP Portfolio With Publication In U.S. Of Its Patent Application For Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines To Treat Post-Traumatic Stress Disorder
Read original at benzinga
CMND
BenzingaAug 24, 2026, 12:54 PMBenzinga Newsdesk
SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders
Read original at benzinga
CMND SPRC TSXV:NTLX
BenzingaAug 13, 2026, 11:36 AMBenzinga Newsdesk
Clearmind Medicine Says DSMB Unanimously Approved Advancing Phase 1/2 Trial Of CMND-100 To Parts B And C In Alcohol Use Disorder Patients And Healthy Participants
Read original at benzinga
CMND